MYC RNAi-PT Combination Nanotherapy for Metastatic Prostate Cancer Treatment
Technical Report,30 Sep 2016,29 Sep 2017
Johns Hopkins University Baltimore United States
Pagination or Media Count:
The main objective of this project is to develop an innovative nanotherapy modality by combining platinum Pt chemotherapy and MYC-targeting RNA interference RNAi for more effective treatment of metastatic prostate cancer PCa. Two specific aims are proposed in this study, including i development and optimization of MYC siRNA-Pt nanoparticles NPs, and 2 determination of the efficacy of select NPs in the B13MYCCrePtenflfl engineered PCa mouse model. This project is directed by an interdisciplinary team in the PCa research field, including Initiating PI Dr. Omid Farokhzad from Brigham and Womens Hospital BWHHarvard Medical School HMS, Partnering PIs Dr. Charles Bieberich from the University of Maryland Baltimore County UMBC and Dr. Angelo De Marzo from the John Hopkins University JHU, and two co-investigators Dr. Srinivasan Yegnasubramanian from JHU and Dr. Jinjun Shi from BWHHMS.
- Medicine and Medical Research
- Genetic Engineering and Molecular Biology